FDA — authorised 25 November 2020
- Marketing authorisation holder: Y-MABS THERAPEUTICS INC
- Status: approved
🇺🇸 Hu3F8 in United States
FDA authorised Hu3F8 on 25 November 2020
Marketing authorisation
Hu3F8 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Hu3F8 approved in United States?
Yes. FDA authorised it on 25 November 2020.
Who is the marketing authorisation holder for Hu3F8 in United States?
Y-MABS THERAPEUTICS INC holds the US marketing authorisation.